Volume 29, Issue 164, October 2025

Advancements in Uterine Fibroid Management: Current Trends and Future Directions

Marta Górska^1♦, Maciej Janowski¹, Jakub Górski², Paweł Czyż³, Antonina Strzałkowska¹

¹Central Teaching Hospital of Medical University of Lodz, Pomorska 251, 92-213, Lodz, Poland
²Medical University of Lodz, Pomorska 251, 92-213, Lodz, Poland
³Szpital Miejski im. Św. Wincentego a Paulo w Gdyni, ul.Wójta Radtkego 18 Gdynia, Poland

^♦Corresponding author
Marta Górska, Central Teaching Hospital of Medical University of Lodz, Pomorska 251, 92-213, Lodz, Poland

ABSTRACT

Uterine fibroids can disrupt daily life. Some women have heavy periods more than expected, and others feel constant lower abdominal pain. Many also face frustration when trying to conceive. Years ago, surgery was usually the first and often only option. But now - thanks to new advances - women have alternatives, choices that are less invasive and frequently easier to manage. Managing fibroids can involve several approaches. One that has gained attention is magnetic resonance imaging– high-intensity focused ultrasound (MR-HIFU). This procedure is (gentle and nonsurgical), using advanced imaging together with concentrated ultrasound energy to concentrate directly on fibroid tissue and gradually shrink it. One treatment option is using oral GnRH antagonists together with hormone therapy (to help balance natural hormones). These medicines can make periods lighter and may help the fibroids get smaller. What makes them especially valuable is that they avoid the issue of bone loss - something that was common with (previous generations of treatment). For some women, however, the earliest steps - whether drug therapy or non-invasive methods - do not fully resolve symptoms. When that happens, the next stage may involve minimally invasive surgery. Approaches such as laparoscopic and robotic techniques are delicate in method, highly controlled, and more exact, offering meaningful advantages, especially for women who wish to protect their fertility and maintain future options.

Keywords: Uterine fibroids, leiomyoma, GnRH antagonists, relugolix, highintensity focused ultrasound (HIFU)

Medical Science, 2025, 29, e206ms3695

PDF

Published: 11 October 2025